ClinicalTrials.Veeva

Menu

Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making

Northwestern University logo

Northwestern University

Status

Enrolling

Conditions

Healthy

Treatments

Device: Real transcranial magnetic stimulation (TMS) before conditioning
Device: Real transcranial magnetic stimulation (TMS) before devaluation test
Device: Sham transcranial magnetic stimulation (TMS)

Study type

Interventional

Funder types

Other

Identifiers

NCT05111223
STU00216104

Details and patient eligibility

About

This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.

Full description

This study will combine functional magnetic resonance imaging (fMRI), non-invasive transcranial magnetic stimulation (TMS), olfactory stimuli, and a devaluation task to define the specific contributions of orbitofrontal cortex (OFC) networks in outcome-guided behavior. We will use network-targeted TMS to modulate activity within anterior OFC and posterior OFC networks, examining if they have different contributions to decision-making. This is a randomized, between-subjects design.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age between 18 and 40 years old
  • Right-handed
  • Fluent English speakers

Exclusion criteria

  • History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)
  • History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, substance use disorder, etc.)
  • Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)
  • Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)
  • Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)
  • Smell or taste dysfunction
  • History of significant allergies requiring hospitalization for treatment
  • History of severe asthma requiring hospitalization for treatment
  • Habitual smoking
  • History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, etc.)
  • Dieting or fasting
  • Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)
  • Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)
  • History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers
  • Claustrophobia
  • Pregnancy
  • Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)
  • Use of medications that increase the likelihood of seizures (e.g., bupropion SR, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)
  • History of surgical procedures performed on the brain or spinal cord
  • History of severe head trauma followed by loss of consciousness
  • History of fainting spells or syncope
  • Hearing problems or tinnitus

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

120 participants in 2 patient groups

TMS targeting OFC anterior networks
Experimental group
Description:
Participants will receive TMS and sham targeting the OFC network.
Treatment:
Device: Sham transcranial magnetic stimulation (TMS)
Device: Real transcranial magnetic stimulation (TMS) before devaluation test
Device: Real transcranial magnetic stimulation (TMS) before conditioning
Experimental: TMS targeting posterior OFC networks
Experimental group
Description:
Participants will receive TMS and sham targeting the posterior OFC network.
Treatment:
Device: Sham transcranial magnetic stimulation (TMS)
Device: Real transcranial magnetic stimulation (TMS) before devaluation test
Device: Real transcranial magnetic stimulation (TMS) before conditioning

Trial contacts and locations

1

Loading...

Central trial contact

Christina Zelano, PhD; Greg Lane, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems